After Novo Nordisk’s Oral Peptide Playbook Made History – Could Entera be The Next Big Peptide Story?

WSW, NY, June 18th, 2026, FinanceWire

At the big endocrinology meetings this season, one story kept stealing the room: the pill that turned an injectable blockbuster into the fastest-moving launch in modern pharma. Novo Nordisk's oral Wegovy - semaglutide, the same GLP-1 peptide millions inject - surpassed three million prescriptions in just over five months, one of the strongest US pharmaceutical launches by volume on record. Framed another way, that's roughly one script every five seconds. And the part that matters most for where the puck is going: more than 80% of those new prescriptions were for people new to GLP-1 therapy - the pill didn't just take share, it grew the market.

Here's the thing almost nobody in that room said out loud. The reason oral Wegovy is a landmark isn't the molecule - semaglutide already existed as a shot. It's that Novo solved the problem that has defined peptide medicine for decades: peptides are among the most effective drugs ever made, but swallow one and your gut digests it before it can work. Cracking oral delivery of a therapeutic peptide is brutally hard - so hard that the conversion math tells the story: it takes a 25 mg oral semaglutide dose to stand in for a 2.4 mg injection. Most of it never makes it through.

Which raises a question worth sitting with: who else might actually be able to do this?

The same playbook - in a market with no oral competition

That's the lens through which to look at Entera Bio (NASDAQ: ENTX), a company most investors still haven't heard of. Entera runs the exact playbook the sector just watched make history - take a proven injectable peptide, deliver it as a once-daily tablet - through a proprietary platform it calls N-Tab. Novo did it for obesity. Entera is doing it for bone.

Its lead candidate, EB613, is an oral tablet of PTH(1-34), the same hormone in Eli Lilly's injectable Forteo - the gold-standard bone-builder that hit roughly $1.7 billion in peak annual sales. The disease underneath is enormous and badly served: an estimated 200 million women worldwide have osteoporosis, the US sees over two million fractures a year, and up to one in five hip-fracture patients dies within a year. The most effective drugs - anabolics like Forteo - already exist. Yet fewer than one in ten high-risk patients ever gets one. The barrier was never the science. It was the needle. That's the same treatment-gap dynamic oral Wegovy just blew open in obesity, where the pill reached millions who'd never touched the injectable.

Fresh from ENDO: the single tablet matches the injection

This isn't a recycled pitch - it's days old. At ENDO 2026 in Chicago, the Endocrine Society's flagship meeting, Entera's EB613 data was selected for a Late-Breaking Oral Presentation - the tier conferences reserve for what the field's own experts consider most consequential, while the overwhelming majority of science gets a poster board.

The data behind that slot, presented June 14, is best understood in context. EB613's efficacy was already established: the multi-tablet version met its endpoints in a 161-patient, placebo-controlled Phase 2 trial published in the Journal of Bone and Mineral Research, producing statistically significant bone-density gains at the spine, hip, and femoral neck. The only thing left to prove was that Entera could deliver that same Phase 2-tested treatment in a single daily pill instead of a multi-tablet regimen. That's what this study did. In a Phase 1 bridging study, the final commercial single tablet delivered a PK/PD profile comparable to both the multi-tablet EB613 that succeeded in Phase 2 and to injectable Forteo itself - similar drug exposure, comparable effect on serum calcium, consistent suppression of the body's own PTH, and a safety profile in line with Forteo, with no drug-related serious adverse events. Just as telling for real-world uptake: of 15 participants, 14 preferred the single tablet to the multi-tablet regimen, and all 15 preferred the daily oral over the daily injection.

The significance is twofold. First, it strips out a layer of late-stage risk: the efficacy is already in hand from Phase 2, and the single tablet now heading into Phase 3 is the exact product that would reach the market - no formulation change left to make. Second, and arguably bigger commercially: collapsing a multi-tablet regimen into one daily pill makes an already Phase 2-tested therapy meaningfully more appealing. In a chronic, symptomless disease where adherence decides everything, one pill a day is exactly what turns proven biology into real-world use - and a far larger market.

Read more on Wall Street Synce >> https://www.wallstreetsync.com/novo-nordisks-oral-peptide-playbook-that-just-made-history-could-entera-be-the-next-multi-billion-dollar-play-nasdaq-entx/

The peptide advantage - and why it echoes the obesity fight

Here's a nuance the obesity race has thrown into sharp relief, and it cuts in Entera's favor. Not every "oral" drug is built the same. Oral semaglutide is a peptide; Lilly's oral obesity contender, orforglipron, is a small molecule - and the difference shows up on the label. Per orforglipron's FDA prescribing information, it's metabolized through the liver's CYP3A4 pathway, must avoid strong CYP3A4 inducers, carries a simvastatin dose cap, and tells patients on oral contraceptives to switch to a non-oral or barrier method. Oral semaglutide, the peptide, carries far fewer such interactions.

That contrast isn't a quirk - it's mechanism. Peptides are broken down into amino acids rather than processed through the CYP450 enzyme machinery that drives most small-molecule drug-drug interactions. EB613 is an oral peptide. While its eventual interaction profile will be defined by its own clinical data and label, it belongs to the drug class that - as the obesity fight is now demonstrating in real time - tends to play more cleanly alongside the other medications older patients are almost always taking. For an osteoporosis population frequently on statins, thyroid medication and more, that's not a footnote.

Not one shot - a platform

EB613 is the lead, not the whole story. At the very same meeting, Entera presented preclinical data on two more oral peptides, both co-developed with OPKO Health: EB612, a long-acting oral PTH tablet for hypoparathyroidism (robust, sustained calcium responses across three animal models; IND targeted for late 2026), and - fittingly - EB618, an oral GLP-1/glucagon tablet for obesity and metabolic disease, which showed dose-proportional exposure and a clear effect on blood glucose in non-human primates.

In short - one small company, one platform, multiple first-in-class oral peptides - including one aimed squarely at the same metabolic space Novo just conquered.

A door that opened for the whole category

The timing isn't luck. For most of a decade, osteoporosis drug development was frozen behind fracture-endpoint trials - thousands of patients over years - and no new drug has been FDA-approved since 2019. That changed in December 2025, when the FDA qualified the change in total hip bone density as a validated surrogate endpoint, the first ever cleared through its Biomarker Qualification Program. Entera had championed that shift since 2022; by its own account it became the first company to win FDA alignment for a single BMD-based Phase 3, and In March 2026, Entera submitted a streamlined Phase 3 protocol, including roughly 750 patients, a 12-month primary endpoint in addition to a 12-month extension study, and critically, its next-generation single tablet as the candidate.

Where the smart money already is

The market has noticed at the edges, even if the crowd hasn't. BVF Partners - the specialist biotech fund behind ChemoCentryx and Blueprint Medicines - led a $10 million investment in April. Former Pfizer Group President Geno Germano, who once ran a roughly $14 billion innovative-medicines portfolio, joined as Chairman in February. The CEO and multiple board members have been buying stock in the open market. All of it sits against a market cap that has hovered around $60 million.

None of this guarantees an outcome. EB613 still has to deliver pivotal Phase 3 data and clear the FDA; the EB612 and EB618 data are preclinical with INDs not yet filed; trials are expensive and can fail. But step back and the contrast is hard to ignore. The world just watched, in real time, what happens when an injectable peptide becomes a pill people will actually take - one of the biggest launches pharma has ever seen, built on reaching the patients the needle left behind. Only a handful of companies have ever cracked oral peptide delivery at all. One of them is running the exact same play in a disease with no oral competition, fresh off data showing its already Phase 2-tested treatment now works in a single daily pill - and it's still valued like nobody's looking.

The crowd is chasing the buzz. The science, again, is somewhere else.

Recent News Highlights from Entera (NASDAQ: ENTX)

Entera Reports Robust Preclinical Data for EB612 (Oral LA-PTH(1-34)) for Hypoparathyroidism and EB618 (Oral GLP-1/Glucagon) for Obesity at ENDO 2026

ENDO 2026 Oral Presentation Highlights Comparative Clinical Data for Entera’s Breakthrough Single Tablet EB613 (First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis)

Entera’s EB613, First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis - Single Tablet Data Selected for Late Breaking Oral Presentation at ENDO 2026 Annual Meeting; Additional Oral Peptide Pipeline Data Accepted for Presentation

Entera Bio to Host Key Opinion Leader Webinar Highlighting the Osteoporosis Treatment Landscape and the Opportunity for EB613

Entera Bio Announces Pricing of $10.0 Million Direct Investment by BVF Partners with Potential for up to $24.5 Million in Total Proceeds

Important Disclaimers and Disclosures: The author, Wall Street Wire, is a content and media technology platform that connects the market with under-the-radar companies. The platform operates a network of industry-focused media channels spanning finance, biopharma, cyber, AI, and additional sectors, delivering insights on both broader market developments and emerging or overlooked companies. Wall Street Wire is not a broker-dealer or investment adviser. References to market size estimates, valuations, price targets, or other third-party data are provided strictly for informational purposes. Wall Street Wire receives cash compensation from Entera Bio Ltd. (the "Issuer") for coverage and awareness services, which are provided on an ongoing subscription basis. The content above is a form of paid advertising and promotion and is for informational purposes only and does not constitute financial or investment advice. This article may contain forward-looking statements about the Issuer's products, plans, or prospects that are subject to risks and uncertainties; actual results may differ materially, and readers should review the Issuer's public filings on SEC EDGAR (sec.gov/edgar) for full risk factors. Market size figures, research estimates, or other third-party data referenced in this article are quoted from publicly available sources believed to be reliable; however, we do not independently verify or endorse them, and additional figures or estimates may exist. Full compensation details, information about the operator of Wall Street Wire, and the complete set of disclaimers and disclosures applicable to this content are available at: wallstwire.ai/disclosures. This article should not be considered an official communication of the Issuer.

Contact